Higher proportion of patients had > 20% reduction in respiratory rate using NHF: 66.7% NHF vs. 38.5% conventional oxygen therapy (COT), p=0.005.
Showed in an ED randomized control trial that NHF was associated with a lower proportion of patients requiring escalation in ventilation therapy.
Nasal high flow can decrease the need for escalation and might decrease the need for intubation
“Patients with HFNC were much more likely to recover from respiratory failure.”
In this edition, we focus on the newly validated ROX index, a bedside tool designed to predict failure in adults, with acute hypoxemic respiratory failure, being treated with Nasal High Flow.
Optiflow Adult Clinical Paper Summaries
Optiflow Newsletter - Issue 6
Optiflow Newsletter - Issue 7
Optiflow Therapy Brochure
If you have an enquiry about our products, please provide the following information so a Fisher & Paykel Healthcare representative can contact you. For further details on how this information will be used, see below or go to our privacy statement.
Sign up to receive email notifications of the latest product and therapy information as well as upcoming events.
Sign up here
A resource center has been created to provide affected hospitals and healthcare professionals with information they may need to treat patients when using Fisher & Paykel Healthcare products.
View resource center
Delivering respiratory support for spontaneously breathing patients
Full face masks designed for comfort and care
Providing Optimal Humidity for intubated patients
Establish effective spontaneous breathing or assist ventilation of the lungs
Respiratory support that replaces spontaneous breathing
Noninvasive respiratory support that provides a continuous distending pressure
Noninvasive respiratory support that delivers high flows of blended air and oxygen
Designed to work in harmony with the way patients naturally breathe while they sleep
F&P SleepStyle - designed to strike the balance between comfort and effective treatment